Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has announced new collaborations with Revatis SA and EXO Biologics on two new research programs, backed by non-dilutive financial backing from the Government of Wallonia in Belgium.
The two research programmes are part of a broader innovation partnership that the Walloon Government has launched with an €81 million budget, dedicated to advanced therapy medicinal products (ATMPs).
Genflow’s partnership with Revatis is dedicated to sarcopenia research.
This three-year endeavour, backed by a €1.34 million grant, targets the progressive loss of muscle mass and function- a critical health issue affecting millions of elderly individuals worldwide.
Simultaneously, the collaboration with EXO Biologics is focused on an mRNA delivery research project.
Supported by a 1.55 million euro grant, this project aims to develop a novel delivery system for Genflow's proprietary centenarian SIRT6 gene using exosomes.
Dr. Eric Leire, chief executive of Genflow, commented: "We are excited to embark on this exciting new research, which aligns with our quest to understand and alleviate the impacts of ageing.
“Launching both of these programs represents a strategic move to enhance our research capabilities, while contributing to the understanding of age-related conditions.
“Both of these strategic initiatives will strengthen Genflow's position at the forefront of ageing-related research, and its mission to improve the health and well-being of older adults."